Dyve Biosciences announced today that it enrolled its first patient in the Phase 2 clinical study of its DYV-700 topically administered therapeutic for acute gout treatment. Thousand Oaks, Calif.–based Dyve won FDA clearance to begin the Targets Phase 2 trial in December 2019. The double-blind, placebo-controlled, randomized clinical trial is set to evaluate the efficacy […]
Dyve Biosciences hires new chief scientific officer
Transdermal drug therapy developer Dyve Biosciences announced that it appointed longtime Pfizer executive Chuck Harbert to the role of chief scientific officer. Harbert spent three decades at Pfizer, serving as the company’s VP of U.S. exploratory development and strategic planning, among other senior positions with Pfizer Central Research. He is the inventor and co-inventor of […]
Dyve Biosciences wins FDA nod for Phase 2 transdermal drug delivery trial
Dyve Biosciences received FDA clearance to begin a Phase 2 study of its DYV-700 transdermal therapeutic for the treatment of acute gout pain. Thousand Oaks, Calif.-based Dyve said it plans to begin the Targets study in the first quarter of 2020. It is slated to be a double-blind, placebo-controlled, randomized clinical trial to evaluate the […]
Dyve Bioscience touts proof-of-concept study for transdermal painkiller
Dyve Bioscience this week touted data from a human proof-of-concept pilot study of its transdermal sodium bicarbonate therapy for pain reduction in people with acute gout flare. The study enrolled 24 people with a history of gout. Those in the active treatment group were given lotion containing sodium bicarbonate and menthol, while those in the […]
